Ralaniten acetate
Ralaniten Acetate
Ralaniten Acetate (pronunciation: rah-lan-ih-ten a-seh-tate) is a non-steroidal antiandrogen that is used in the treatment of prostate cancer. It is also known by its developmental code name EPI-506.
Etymology
The name "Ralaniten" is derived from the chemical structure of the compound, which includes a ralanite moiety. The "acetate" part of the name refers to the presence of an acetate group in the chemical structure.
Pharmacology
Ralaniten acetate works by binding to the androgen receptor, thereby preventing androgens (male hormones) from binding to the receptor and stimulating the growth of prostate cancer cells. It is a derivative of ralaniten, a compound that was originally developed as a treatment for benign prostatic hyperplasia (BPH).
Clinical Use
Ralaniten acetate is currently being investigated in clinical trials for the treatment of prostate cancer. It is specifically being studied for use in patients with castration-resistant prostate cancer (CRPC), a form of the disease that is resistant to traditional hormone therapy.
Related Terms
- Antiandrogen
- Androgen receptor
- Androgens
- Prostate cancer
- Castration-resistant prostate cancer
- Hormone therapy
- Benign prostatic hyperplasia
- Ralaniten
External links
- Medical encyclopedia article on Ralaniten acetate
- Wikipedia's article - Ralaniten acetate
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski